Background
The mechanisms of adult brain repair and structural plasticity have been the subject of intensive investigation since the discovery of adult neural stem cell (NSC) niches and their ability to proliferate and differentiate into new neurons and glial cells [
1,
2]. New neurons in the adult brain are produced in discrete neurogenic niches, primarily the subventricular zone (SVZ) and the subgranular zone (SGZ) in the hippocampal dentate gyrus (DG) [
2,
3]. In turn, production of new oligodendrocytes in adulthood originates primarily from endogenous oligodendrocytes progenitor cells (OPCs) that are widely distributed throughout the CNS [
4] and are the major source of remyelinating oligodendrocytes after demyelinating insults [
5]. OPC survival/proliferation, migration to the site of injury and differentiation into mature oligodendrocytes are critical for successful remyelination and are often compromised after injury [
1,
6]. Aging, as well as acute brain injury and neurodegenerative diseases, or psychiatric disorders like depression, are associated with a decline and/or dysfunction in neurogenesis [
2,
7]. Thus, strategies aimed to enhance and/or redirect endogenous neurogenesis and oligodendrogenesis, e.g. through the pharmacological manipulation of the neurogenic microenvironment, represent an attractive and powerful therapeutic tool.
FTY720, a structural analogue of sphingosine, is principally known as oral drug for multiple sclerosis [
8]; its bio-active form, FTY720-phosphate (FTY720-P) that mimics the structure of sphingosine-1-phosphate (S1P) and derives, in turn, from the phosphorylation by sphingosine kinase 2, is a potent S1P receptor (S1PR) modulator [
9]. Interestingly, the ability of FTY720 to pass BBB and to act, following in vivo phosphorylation, through S1PRs expressed in CNS makes this drug extremely versatile, and a number of direct effects on neurons, microglia, oligodendrocytes and astrocytes have been demonstrated [
10]. The regenerative capacitive of FTY720 has been observed both in vitro and in vivo. FTY720 promotes OPC proliferation and differentiation in vitro [
11‐
13], and in vivo in experimental autoimmune encephalomyelitis (EAE) mice model [
14], and increases the number of newly produced myelinating cells in a model of local demyelination induced by lysolecithin (LPC) [
15] or enhances the proliferation and migration of transplanted neural progenitor cells (NPCs) in a model of viral-induced demyelination [
16]. Also, a certain ability of FTY720 to induce NPC differentiation predominantly toward oligodendroglial lineage has been observed in vitro and after transplantation in mice brain [
17].
FTY720 shows positive effects on survival, proliferation, migration and differentiation of NSCs in vitro [
18‐
21]. In addition, in vivo chronic treatment with FTY720 increases proliferation, survival and formation of new neurons in healthy mouse hippocampus [
19,
20], improving contextual fear memory [
19] and enhanced learning and memory ability [
20]. Interestingly, FTY720 treatment enhances adult neurogenesis in the hippocampal DG of mice exposed to chronic unpredictable stress [
22], an experimental paradigm of depression, causing an enhanced production of BDNF and resulting in antidepressant-like effect. However, the role of FTY720 as neuro/oligogenic agent remains not fully elucidated, especially in pathological conditions. FTY720 would be good candidate to modulate the microenvironment through the production of neurothophic factors [
23,
24] and to modulate the neuroinflammatory response. Moreover, S1PR signalling plays a relevant role in the regulation of neurogenesis and cellular plasticity [
25,
26].
In the present study, we investigated the effects of FTY720 on the modulation of SVZ and SGZ neurogenic niches, and the production of new neurons and oligodendrocytes following injury induced by intracerebroventricular (icv) injection of kainic acid (KA), a glutamate receptors agonist, in rats.
Methods
FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol) powder was gently provided by Novartis.
Animals
All procedures and experiments involving animals and their care were carried out according to the guidelines of the European Union Council (Directive 2010/63/EU) and Spanish regulations (Real Decreto 53/2013) on animal ethics and welfare, and under the supervision and with the approval of our internal animal ethics committee (University of the Basque Country, UPV/EHU). All possible efforts were made to minimize animal suffering and the number of animals used.
Neurosphere cultures and differentiation assay
NSC cultures were prepared from 4 to 7-day-old Sprague-Dawley rat pups, as previously described [
27,
28], with slight modifications. Briefly, the SVZ was isolated and minced with a McIlwain tissue chopper. SVZ tissue from three to four brains was digested for 7 min at 37 °C in 5 ml of trypsin/EDTA (Sigma). Digestion was stopped by adding an equal volume of trypsin inhibitor (Gibco) and 0.01% DNAse I (Sigma) for 5 min at room temperature. The cell suspension was centrifuged for 10 min at ×600
g and the pellet mechanically dissociated 25 times in 3 ml NeuroCult
TM medium (STEMCELL Technologies) using a glass Pasteur pipette and 20 times using 1 ml pipette tips. The cells that remained in suspension were decanted for 20 min and the single cell suspension counted using the Neubauer method. Cells were seeded in proliferation medium [NeuroCult
TM medium supplemented with 10% neural stem cell factors from STEMCELL Technologies, 2 mM glutamine, penicillin/streptomycin mix, 20 ng/ml EGF/epidermal growth factor (Promega), 10 ng/ml bFGF/basic fibroblast growth factor (Promega), 10 ng/ml PEDF/pigment epithelium-derived factor (Millipore)] at a density of 10
4cells/cm
2 and cultivated in suspension for 7 days at 37 °C, 5% CO
2. EGF, bFGF and PEDF were added fresh every 2–3 days. After 7 DIV (days in vitro), cells were aggregated as neurospheres. To differentiate cultures from neurons, floating neurospheres were then allowed to attach onto poly-ornithine-coated glass coverslips in 24-well plates in neuron differentiation medium (NeuroCult™ medium supplemented with differentiation factor 10× (both from STEMCELL Technologies), NGF/nerve growth factor (NGF-beta, human recombinant, #4303R-100; Biovision) and BDNF/brain-derived neurotrophic factor (BDNF, human recombinant, #4004–50; Biovision)) and differentiated for additional 7 DIV in the presence of FTY720 (reconstituted in dimethyl sulfoxide hydrochloric acid (DMSO)/50 mM HCl). Alternatively, the neurospheres were maintained for 3 days in oligodendrocyte differentiation medium, composed of DMEM supplemented with 4.5 mg/ml glucose and sodium pyruvate (Gibco), SATO (100× stock solution: 100 μg/ml BSA, 100 μg/ml transferrin, 16 μg/ml putrescine, 40 ng/ml thyroxine, 30 ng/ml tri-iodothryronine, 60 ng/ml progesterone, 40 ng/ml selenium, all of from Sigma), 6.3 mg/ml N-acetyl-cysteine (Sigma), 0.5 mg/ml insulin (Sigma), 1 μg/ml CNTF/ciliary neurotrophic factor and 10 μg/ml NT3/neurotrophin-3 (both from Peprotech). This step was considered to be the
pre-commitment stage before oligodendrocyte differentiation. After 3 DIV, floating neurospheres were allowed to attach onto poly-ornithine-coated glass coverslips in 24-well plates in oligodendrocyte differentiation medium and differentiated for 4 DIV in the presence of FTY720.
At the end of the differentiation phase, on DIV 14, cells were fixed and immunostained for cell-specific markers of mature neurons or oligodendrocytes. The extent of differentiation both to neurons and to oligodendrocytes was evaluated in treatment conditions and control conditions as described below.
Immunocytochemistry and evaluation of neurospheres differentiation
Following differentiation, cell cultures were fixed in 4% paraformaldehyde and permeabilized with 0.05% Triton and 5% normal goat serum in phosphate-buffered saline (PBS). Primary antibody rabbit, anti-β-III tubulin (1:300; Abcam, #Ab18207) and mouse anti-CNPase (1:500; Sigma, #C5922) were incubated overnight at 4 °C and then washed three times with 0.05% Triton in PBS. Alexa Fluor 488-conjugate secondary antibodies were incubated for 1 h in the dark at room temperature (1:500). After three washes with 0.05% Triton in PBS, cells were stained for 10 min at room temperature with propidium iodide (PI) to stain total nuclei, and further washed with PBS. Fluorescence intensity was measured using a fluorescence microplate reader equipped with appropriate excitation and emission filters to detect the fluorescent signal from Alexa 488 and PI. Differentiation was evaluated as a ratio of fluorescence intensity from β-III tubulin or CNPase-positive cells over total nuclei.
Intracerebroventricular injection of KA, FTY720 treatment and BrdU labelling in adult rats
We used a total of 24 adult male Sprague-Dawley rats (200–250 g). Rats were kept on a 12/12 h light/dark cycle with constant ambient temperature and humidity. Food and water were available ad libitum. We used unilateral
icv injection of KA as model of induced-seizure and neurodegeneration. Rats (
n = 6 per experimental group) were anesthetized by
ip of ketamine 80 mg/kg (Imalgene®, Merial Laboratorios SA) and xylazine 10 mg/kg (Rompun®, Bayer) and placed into a stereotaxic apparatus (David Kopf Instruments). KA (0.5 μg in 2 μl in saline; Abcam), alone or in combination with FTY720 (1 μg in 2 μl in saline), was injected into the right lateral ventricle (right side referred thereafter as ipsilateral), at the following coordinates from bregma: −1 mm anterioposterior, 2 mm mediolateral and 4 mm dorsoventral [
29]. Injections were carried out over 5-min period using an infusion pump (KD Scientific), with a constant infusion rate of 0.4 μl/min. Animals were injected
ip with vehicle (saline solution) or FTY720 (1 mg/kg) 24 h before
icv injection and subsequent daily until sacrifice 8 days after KA application (see Fig.
2a for experimental design). For the
ip injection, FTY720 was freshly prepared every day. Control animals received vehicle only. All animals received the thymidine analogue 5-bromo-2′-deoxyuridine (BrdU, Sigma, #B5002) as
ip injection (100 mg/kg, diluted in sterile saline) every 2 days starting the day after
icv injection, as previously used [
30]. Rats were sacrificed 24 h after the last BrdU injection.
Histology
Eight days after icv injection, the animals were deeply anesthetized with chloral hydrate 400 mg/kg (Panreac Quimica) and transcardially perfused with 4% paraformaldehyde in 0.1M PBS (pH 7.4). Brains were removed and immediately post-fixed in the same solution for 3 h. Then, they were washed and stored at +4 °C in PBS/Azide (0.02%) until sectioning. For all brains, series of 40-μm-thick coronal sections at the level of lateral ventricles and dorsal hippocampus were cut on a vibratome (HM 650V, Microm International) and used for immunohistology on free-floating sections, as hereinafter described. HCl antigen retrieval was used for BrdU immunostaining: before blocking step, sections were incubated in 2N HCl at 37 °C for 30 min to denature DNA, followed by two 10-min rinses in 0.1M sodium tetraborate pH 8.5 at room temperature to neutralize HCl and then rinsed twice with PBS. Immunoperoxidase staining was used for identification of proliferating, BrdU-positive nuclei. Briefly, after quenching of endogenous peroxidase (H2O2 0.3%) and blocking/permeabilization (4% normal goat serum and 0.1% Triton X-100 in PBS), we incubated the sections overnight at 4 °C with a rat anti-BrdU antibody (AbD Serotec, #MCA2060) diluted 1:400 in blocking buffer. Subsequently, the primary antibody was detected using biotinylated goat anti-rat secondary antibodies (1:200), followed by incubation with avidin-biotin-peroxidase complex (both from Vector Laboratories). Peroxidase activity was visualized by incubation in 3,3′-diaminobenzidine (DAB) substrate (Roche). Finally, the sections were mounted in gelatin-coated slides, dehydrated through graded alcohols, cleared with xylene and coverslipped with DPX.
To analyze the cell fate of BrdU-positive cells, we performed double immunofluorescence colocalization studies with cell-specific markers. The sections were incubated with blocking and permeabilization solution (4% normal goat serum, 0.1% Triton X-100 in PBS) for 1 h at room temperature and then incubated overnight with the primary antibodies (diluted in the same solution) at 4 °C. After washing with PBS, the sections were incubated with Alexa Fluor 488- or 594-conjugate secondary antibodies (molecular probes) diluted 1:400 in the blocking solution for 1 h at room temperature. After washing with PBS, the sections were mounted on gelatine-coated slides with ProLong® Antifade Mountant (ThermoFisher Scientific). In addition to anti-BrdU antibody, we used rabbit anti-DCX (1:1000; Abcam, #Ab18723) as a marker of new neurons and mouse anti-NG2 (1:500; Chemicon, #MAb5384) as a marker of OPCs.
Negative controls in all experiments included the omission of the primary antibodies and provided no labelling, indicating the reliability and specificity of the immunostaining.
Image capture and cell quantification
Immunoperoxidase staining
Two slices per animal were analyzed representing two different levels of the dorsal hippocampus. The sections were visualized using Zeiss Axioplan 2 bright field microscope coupled to an Axiocam MRc5 digital camera (Zeiss), and representative photomicrographs of ipsilateral and contralateral DG region of the hippocampus were taken under a ×10 magnification objective. Quantitative analysis of BrdU-positive cells was performed counting the immunoreactive cells along the whole SGZ of DG in each slice under ×40 magnification objective. BrdU-positive cells were considered to be within the SGZ if they were within two cell body diameters on the border between the granular cell layer (GCL) and the hilus (see Fig.
2b) [
31]. Immunoreactive cells were counted in two slices per animals, and data were plotted as the mean of BrdU-positive cells per section ± SEM.
Colocalization analysis
To analyze cell fate of newly, BrdU
+ cells, double-immunolabelled sections were imaged with a Fluoview FV500 confocal laser scanning microscope (Olympus) equipped with Fluoviewer software (Olympus). Positive cells were counted using confocal acquired images, and the percentage of BrdU
+ cells colabelling with cell fate markers was determined using Z-stack maximal projection of 5–10 confocal layers spaced 2.5 μm in coordination with three-dimensional orthogonal reconstruction of confocal layers (ImageJ software,
http://rsbweb.nih.gov/ij/download.html). DCX and BrdU colocalization was determined over the total ipsilateral SGZ of DG in two slices per animal corresponding to two different levels of the dorsal hippocampus, and data is presented as mean positive cells per section in the case of total BrdU
+ cells and as percentage of DCX/BrdU double-positive cells on total BrdU
+ cells per section. NG2 and BrdU colocalization was determined at the level of lateral ventricle and at the level of the dorsal hippocampus: the measured areas selected five fields of the corpus callosum (both at ventricle and hippocampal levels), three fields of hilus and two fields of fimbria of the dorsal hippocampus (see Figs.
4a and
5d). Data are illustrated as the average of positive cells per square millimeter (mm
2) in the case of total BrdU
+ cells and percentage of NG2/BrdU double-positive cells on total BrdU
+ cells per mm
2.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analyses were performed using Prism version 5.0 (GraphPad Software, USA). Comparisons between the two groups were analyzed using two-tailed Student’s t test. Comparisons among multiple groups were analyzed by one-way or two-way analysis of variance (ANOVA), as appropriate, followed by Bonferroni post hoc test. p ≤ 0.05 or p ≤ 0.01 was defined as significant or highly significant, respectively.
Discussion
In the present study, we provide evidence for a proneurogenic effect of FTY720 in vitro, whereby this drug favours the differentiation of postnatal SVZ-derived NSCs into both neurons and oligodendrocytes. In turn, in adult animals, FTY720 increases in the number of new neuroblasts in SGZ following KA-mediated injury. The OPC population is only partially affected by FTY720 treatment, depending on the analyzed regions.
Postnatal and adult NSCs could have different differentiation potentials, although a recent study in vitro reported a similar behaviour of postnatal (p7) and adult (p42)-derived NSCs [
28]. Despite this consideration, we decided to use adult animals for the in vivo protocol as the main aim of our study was to examine the response of neurogenic niches to FTY720 after injury.
KA-induced status epilepticus (SE) is an extensively used seizure model of temporal lobe epilepsy in rodents and results primarily in a reproducible pattern of excitotoxic hippocampal cell death [
35,
36], as well as in a robust neuroinflammatory response and gliosis [
37,
38]. KA-induced seizures in rodents also increase neurogenesis in DG, but in an aberrant and possibly pathogenic way [
39]. In fact, KA-induced neurogenesis is accompanied by immature neurons and granule cell dispersion within the adult GCL, widening of the hippocampal GCL, abnormal morphology of newborn neurons and mossy fiber sprouting, abnormal connectivity of newborn neurons into the hippocampal circuits [
2,
31,
40‐
43]. Increase of neurogenesis after SE is considered predominantly detrimental, contributing to epileptogenesis and chronic epilepsy [
31], as well as to NSCs pool depletion in SGZ [
44]. On the other hand, aging affects hippocampal neurogenic response to seizures with a shift toward glial differentiation, and severe cognitive deficits and chronic epilepsy transformation [
45,
46]. Interestingly, SE-induced epileptogenesis is not disrupted in cyclin D2 knockout mice which has a markedly reduced adult neurogenesis [
47]. Therefore, the functional relevance of increased neurogenesis after seizure remains doubtful [
31,
48] though it is assumed that the neurogenic response after acute seizure activity occurs as an endogenous repair mechanism.
In this study, we observed an increase of proliferating cells after KA-induced injury which was not modulated by FTY720. Interestingly, FTY720 favours a neuronal fate choice of newly born cells, as a significant number of BrdU
+ cells are also DCX
+. Thus, FTY720 redirects endogenous neurogenesis to a neuronal fate which may contribute to the previously observed improved neuronal outcome in this injury paradigm [
32]. These findings are in line with those showing enhanced hippocampal neurogenesis and memory after chronic administration with FTY720 in adult mice [
19,
20] and in mice subjected to chronic unpredictable stress, an experimental paradigm of depression [
22]. However, further analysis will be require to verify morphology, integration in GCL, and functionality of new neuroblasts in FTY720-treated animals in our experimental conditions and at longer time points after injury. The use of later markers for fully mature neurons (e.g. NeuN) in combination with BrdU staining would allow to determine whether the neurogenic potential of FTY720 is long-lasting and whether DCX-positive cells can exhibit long-term survival in the SGZ–GCL and constitute a proportion of mature granule cells. FTY720 also reduces microgliosis and brain inflammation after KA-induced SE [
32,
49]. Pro-inflammatory microglia have a negative impact on neurogenesis [
50,
51], thus FTY720, modulating the inflammatory response, may exert its proneurogenic activity modifying the microenvironmental milieu after acute injury.
Mobilization of OPC population after demyelinating injury represents an attractive therapeutic strategy to support remyelination and consequently brain function. Zhang and colleagues recently demonstrated that FTY720 promotes proliferation and differentiation of OPCs in EAE mice model, in the SVZ, striatum, corpus callosum, and white matter spinal cord, by activating pathways of oligodendrogenesis [
14]. OPCs and oligodendrocytes are susceptible to excitotoxic damage, and myelin degeneration has been observed at various time points and in different brain regions after KA-induced neuronal death [
52]. Therefore, KA-induced acute injury represents a good model to test the oligodendrogenic effect of FTY720, and as previous studies have demonstrated how pilocarpine-induced SE increases SVZ gliogenesis and attracts newly generated glia to regions of hippocampal damage [
53]. Nevertheless, in our experimental conditions, after treatment with FTY720, we found a small, though significant, change in the number of newly generated OPC/NG2 cells in the analyzed area. Thus, in the corpus callosum at the level of dorsal ipsilateral hippocampus, near the most profusely damaged area, we observed a significant increase of newly generated NG2
+ cells in KA + FTY720-treated group compared to KA-treated animals, and the effect was maintained when we pooled together data from all analyzed regions. However, the effect was lost at more distal white matter regions, such as the corpus callosum at the level of lateral ventricles. Additional studies are needed to better understand the role of FTY720 on oligodendrogenesis in pathological conditions, mostly at later disease stages.
Alternatively, to enhance repair by endogenous NSCs, neuronal or oligodendrocyte lost after disease can be replaced by engraft of exogenous stem cells [
54]. However, this therapeutic strategy may be limited due to cell death of transplanted cells, rejection of donor cells and tumorigenesis [
55]. In our study, we demonstrated the ability of the pro-drug FTY720, in its non-phosphorylated form, to promote differentiation of postnatal NSCs into both neurons and oligodendrocytes; therefore, FTY720 may be a promising drug for the manipulation of NSC pool used in stem cells graft therapies, promoting their survival, proliferation and oriented differentiation, as well as integration [
17,
18]. The active form of FTY720 is considered the phosphorylated one; however, a growing literature demonstrates the effectiveness of the non-phosphorylated form of FTY720 not only in vivo, where FTY720 can be phosphorylated by endogenous sphingosine kinase 2, but also in vitro [
17,
18,
20,
32,
56‐
58]
. In our NSC cultures, we cannot exclude that the effect observed with FTY720 is due to phosphorylation FTY720-P by sphingosine kinases eventually present in the cultures, as reported elsewhere [
17,
58]. In effect, experiments performed with FTY720-P are in support of this hypothesis (Additional file
1: Figure S1), that is the effect we showed in Fig.
1 is due to S1P receptors modulation.